Latest Ischaemic heart disease Stories
BOTHELL, Wash., Aug. 19, 2011 /PRNewswire/ -- Verathon Inc.
New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).
A new study reveals having a CT angiography test leads to more prescriptions for medications, more tests, and more procedures.
A new study of coronary artery calcium scanning â€“ a simple, noninvasive test that gives patients baseline information about plaque in their coronary arteriesâ€”has shown that the scan helps them make heart-healthy lifestyle changes and lower their heart disease risk factors.
Never before has a therapy proven more beneficial for women than men in preventing heart disease â€“ until now.
Two relatively simple methods, an ultrasound investigation and a blood test to measure the level of a substance known as BNP, can predict survival and future heart failure following acute coronary syndromes.
A European study investigating the links between diet and disease has found that people who consume more fruit and vegetables have a lower risk of dying from ischaemic heart disease â€“ the most common form of heart disease and one of the leading causes of death in Europe.
TEL AVIV, Israel, December 13, 2010 /PRNewswire-FirstCall/ -- Biological Signal Processing Ltd.
BAAR, Switzerland and TEL AVIV, November 22, 2010 /PRNewswire-FirstCall/ -- SCHILLER AG, a leading international manufacturer and supplier of cardiopulmonary diagnostics and BSP Biological Signal Processing Ltd., a medical device company that develops and markets innovative solutions for noninvasive cardiac diagnosis and monitoring , announced on November 8th, 2010 the signing of an agreement to jointly develop a new product line based on BSP's HyperQ(TM) technology.
PARIS, August 30, 2010 /PRNewswire/ -- - Composite Primary Endpoint: Risk Reduction of 17% (Non-Statistically Significant ) in Death, Complication of Myocardial Infraction, Procedure Failure or Major Bleeding (p=0.07) - Main Secondary Composite Efficacy Endpoint: 40% Reduction of Death, Recurrent Acute Coronary Syndrome or Re-Intervention (p=0.01) The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite...
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.